On August 25, 2026, India’s Central Bureau of Narcotics (CBN) and the Pharmacy Export Promotion Council of India (PHARMEXCIL) signed a Memorandum of Understanding (MoU) to strengthen regulatory oversight of controlled substances in pharmaceutical exports. The agreement, reported by ANI News, The Economic Times, Express Pharma, and multiple other outlets, aims to prevent the diversion of narcotic and psychotropic substances used in legitimate medicines during the export supply chain.<\/p>\n\n\n\n
The MoU establishes a framework for coordination between CBN \u2014 India’s narcotics control agency under the Ministry of Home Affairs \u2014 and PHARMEXCIL, the government-promoted export promotion council for the pharmaceutical sector. Under the agreement, the two bodies will share intelligence, streamline export licensing for controlled substances, and implement stricter tracking mechanisms to ensure that psychotropic and narcotic drugs exported as legitimate medicines do not get diverted to illegal channels.<\/p>\n\n\n\n
Many essential medicines contain controlled substances \u2014 ingredients classified under international narcotics and psychotropic conventions. These include opioid analgesics (such as morphine and fentanyl patches) used in pain management, codeine-based cough preparations, benzodiazepines prescribed for anxiety and sleep disorders, and certain stimulants used in attention-deficit treatments. India is a significant exporter of generic formulations containing these substances, particularly to markets in Africa, Asia, and the Americas. Without robust export controls, there is a risk that legitimate pharmaceutical shipments could be intercepted, diverted, or misused \u2014 damaging both public health and India’s reputation as a reliable supplier.<\/p>\n\n\n\n
For international buyers sourcing Indian generic medicines that contain controlled substances, the MoU signals tighter export controls and potentially longer clearance times for shipments of pain medications, cough preparations, and other formulations containing narcotic or psychotropic ingredients. Buyers should:<\/p>\n\n\n\n
This MoU is part of a broader effort by Indian regulatory bodies to strengthen the country’s pharmaceutical export infrastructure. In 2026, CDSCO has moved to digitize drug regulatory processes and pilot AI-driven oversight systems, while PHARMEXCIL continues to promote Indian generic medicines in global markets. The CBN-PHARMEXCIL agreement addresses a specific gap \u2014 the need for coordinated narcotics control in the export supply chain \u2014 that had been identified as a risk by both industry and government.<\/p>\n\n\n\n